ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Quarterly Earnings Results, Beats Expectations By $0.11 EPS

ACADIA Pharmaceuticals (NASDAQ:ACAD) posted its earnings results on Tuesday. The biopharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11, FiscalAI reports. ACADIA Pharmaceuticals had a return on equity of 9.38% and a net margin of 33.42%.The firm had revenue of $308.00 million during the quarter, compared to analysts’ expectations of $296.55 million. During the same period in the previous year, the firm earned $0.16 earnings per share. The company’s revenue was up 16.4% on a year-over-year basis.

Here are the key takeaways from ACADIA Pharmaceuticals’ conference call:

• Second-quarter revenue rose 17% to $308 million on an adjusted basis, driven by strong demand for both DAYBUE and NUPLAZID.
• DAYBUE sales increased 30% to $125 million, with DAYBUE STIX adopted by approximately 40% of U.S. patients by quarter-end and helping bring discontinued patients back to treatment. ACADIA raised its 2026 DAYBUE guidance to $480 million–$510 million.
• NUPLAZID sales grew 10% to $183 million, while new patient prescriptions rose 20% year over year. Management said the expanded field force is beginning to contribute and maintained its goal of approximately $1 billion in 2028 NUPLAZID sales.
• DAYBUE received a positive CHMP opinion in Europe, with a European Commission decision expected by the end of the third quarter and a planned German launch in early fourth quarter. Management expects Europe to represent less than half of its $700 million 2028 DAYBUE sales target.
• The key pipeline catalyst is the phase II RADIANT readout for remlifanserin in Alzheimer’s disease psychosis, now expected in September–October after enrollment of 363 patients. ACADIA has begun phase III screening, but the program remains dependent on demonstrating clinically meaningful efficacy and a supportive safety profile.

ACADIA Pharmaceuticals Stock Performance

NASDAQ:ACAD opened at $28.80 on Thursday. ACADIA Pharmaceuticals has a 52 week low of $19.69 and a 52 week high of $29.17. The firm’s 50-day simple moving average is $24.10 and its 200 day simple moving average is $23.22. The firm has a market cap of $4.93 billion, a price-to-earnings ratio of 12.97, a P/E/G ratio of 18.82 and a beta of 0.81.

Trending Headlines about ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Quarterly earnings and revenue beat expectations. ACADIA reported second-quarter EPS of $0.18 versus the $0.07 consensus estimate, while revenue reached $308 million, above expectations of $296.6 million and up 16.4% year over year. ACADIA Pharmaceuticals second-quarter earnings report
• Positive Sentiment: Product sales supported the outlook. Strong demand for DAYBUE and NUPLAZID helped drive the quarterly performance, and ACADIA raised its 2026 revenue guidance to $1.2 billion-$1.3 billion, broadly above or in line with the prior consensus view. ACADIA earnings and revenue outlook
• Positive Sentiment: Citizens JMP raised its price target. The firm increased its target from $35 to $36 and maintained a “Market Outperform” rating, signaling additional potential upside based on ACADIA’s commercial momentum. ACADIA price-target update
• Neutral Sentiment: HC Wainwright made mixed estimate revisions. The analyst raised its Q3 2026 EPS estimate to $0.15 from $0.13 and FY2027 estimate to $1.89 from $1.70, but trimmed its Q4 2026 estimate to $0.20 from $0.21. The firm maintained a “Hold” rating, tempering the otherwise positive earnings reaction.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Oppenheimer lifted their price objective on shares of ACADIA Pharmaceuticals from $23.00 to $25.00 and gave the company a “market perform” rating in a report on Wednesday. Royal Bank Of Canada upped their target price on ACADIA Pharmaceuticals from $36.00 to $37.00 and gave the stock an “outperform” rating in a report on Wednesday. Weiss Ratings reiterated a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday, July 29th. Canaccord Genuity Group raised their price target on ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, Bank of America reiterated a “buy” rating and issued a $14.50 price objective on shares of ACADIA Pharmaceuticals in a report on Wednesday, July 29th. Fourteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, ACADIA Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $32.53.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $26.13, for a total value of $432,660.54. Following the completion of the transaction, the executive vice president directly owned 18,994 shares in the company, valued at approximately $496,313.22. This trade represents a 46.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider James Kihara sold 5,401 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total transaction of $114,393.18. Following the completion of the transaction, the insider owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. This trade represents a 18.06% decrease in their position. The SEC filing for this sale provides additional information. 26.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of institutional investors have recently modified their holdings of ACAD. Meeder Asset Management Inc. bought a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter valued at $26,000. Transamerica Financial Advisors LLC raised its holdings in shares of ACADIA Pharmaceuticals by 304.5% in the fourth quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 1,005 shares during the last quarter. Federated Hermes Inc. lifted its position in shares of ACADIA Pharmaceuticals by 277.5% during the fourth quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 1,185 shares in the last quarter. Smartleaf Asset Management LLC grew its position in ACADIA Pharmaceuticals by 51.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,596 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 884 shares in the last quarter. Finally, iSAM Funds UK Ltd bought a new position in shares of ACADIA Pharmaceuticals during the 3rd quarter worth approximately $93,000. 96.71% of the stock is owned by institutional investors.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.